504 related articles for article (PubMed ID: 26558806)
1. Potential therapeutic approaches for Angelman syndrome.
Bi X; Sun J; Ji AX; Baudry M
Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
[TBL] [Abstract][Full Text] [Related]
3. Therapies in preclinical and clinical development for Angelman syndrome.
Markati T; Duis J; Servais L
Expert Opin Investig Drugs; 2021 Jul; 30(7):709-720. PubMed ID: 34112038
[No Abstract] [Full Text] [Related]
4. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
Elgersma Y; Sonzogni M
Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
[TBL] [Abstract][Full Text] [Related]
5. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
6. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
7. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
[TBL] [Abstract][Full Text] [Related]
8. Adult
Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
[TBL] [Abstract][Full Text] [Related]
9. Ube3a imprinting impairs circadian robustness in Angelman syndrome models.
Shi SQ; Bichell TJ; Ihrie RA; Johnson CH
Curr Biol; 2015 Mar; 25(5):537-45. PubMed ID: 25660546
[TBL] [Abstract][Full Text] [Related]
10. Towards an understanding of Angelman syndrome in mice studies.
Yang X
J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
[TBL] [Abstract][Full Text] [Related]
11. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
12. Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
Jamal I; Kumar V; Vatsa N; Shekhar S; Singh BK; Sharma A; Jana NR
Neurobiol Dis; 2017 Sep; 105():99-108. PubMed ID: 28576709
[TBL] [Abstract][Full Text] [Related]
13. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes.
Mabb AM; Judson MC; Zylka MJ; Philpot BD
Trends Neurosci; 2011 Jun; 34(6):293-303. PubMed ID: 21592595
[TBL] [Abstract][Full Text] [Related]
14. Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.
Lopez SJ; Laufer BI; Beitnere U; Berg EL; Silverman JL; O'Geen H; Segal DJ; LaSalle JM
Hum Mol Genet; 2019 Nov; 28(22):3842-3852. PubMed ID: 31625566
[TBL] [Abstract][Full Text] [Related]
15. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the
Dindot SV; Christian S; Murphy WJ; Berent A; Panagoulias J; Schlafer A; Ballard J; Radeva K; Robinson R; Myers L; Jepp T; Shaheen H; Hillman P; Konganti K; Hillhouse A; Bredemeyer KR; Black L; Douville J; ;
Sci Transl Med; 2023 Mar; 15(688):eabf4077. PubMed ID: 36947593
[TBL] [Abstract][Full Text] [Related]
16. PKA and Ube3a regulate SK2 channel trafficking to promote synaptic plasticity in hippocampus: Implications for Angelman Syndrome.
Sun J; Liu Y; Zhu G; Cato C; Hao X; Qian L; Lin W; Adhikari R; Luo Y; Baudry M; Bi X
Sci Rep; 2020 Jun; 10(1):9824. PubMed ID: 32555345
[TBL] [Abstract][Full Text] [Related]
17. Angelman syndrome - insights into a rare neurogenetic disorder.
Buiting K; Williams C; Horsthemke B
Nat Rev Neurol; 2016 Oct; 12(10):584-93. PubMed ID: 27615419
[TBL] [Abstract][Full Text] [Related]
18. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
19. [From pathogenesis to treatment of genetic intellectual disabilities: a lesson from Angelman syndrome research].
Saitoh S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Jun; 33(3):127-30. PubMed ID: 25069246
[TBL] [Abstract][Full Text] [Related]
20. A bipartite boundary element restricts
Hsiao JS; Germain ND; Wilderman A; Stoddard C; Wojenski LA; Villafano GJ; Core L; Cotney J; Chamberlain SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2181-2186. PubMed ID: 30674673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
